A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor in preclinical models of ALL and AMLWATERTOWN, Mass., June 09, 2023 . | June 9, 2023
/PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway,.
Researchers Report Clinical Proof-of-Concept Data for Vivace Therapeutics' VT3989, a First for a Cancer Drug Targeting the Hippo Pathway, in Oral Presentation at AACR 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SAN MATEO, Calif., May 4, 2021 /PRNewswire/ Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the completion of enrollment of the first cohort of patients being treated with VT3989 in its Phase 1 clinical study. The Company anticipates enrolling the next higher dose cohort in the second part of May.
The VT3989 Phase 1 study is now open at centers in both the US and Australia (https://clinicaltrials.gov/ct2/show/NCT04665206) to evaluate the safety, tolerability, PK and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory pleural malignant mesothelioma. The study is currently in dose escalation, to be followed by a dose expansion phase in which patients with